The company expects to grant the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock to cover over-allotments, if any.
Luminex intends to use the net proceeds from the offering for general corporate purposes, including research and development, potential acquisitions and capital expenditures.
JP Morgan Securities and UBS Investment Bank are acting as joint book-running managers for the offering.